CN Patent

CN107108624B — 用于治疗耐药性细菌感染的组合疗法

Assigned to Ntassis Treatment · Expires 2020-01-07 · 6y expired

What this patent protects

本发明涉及β‑内酰胺酶抑制剂与舒巴坦及任选的亚胺培南/西司他丁的组合。所述组合适用于治疗细菌感染，包括由包括多重耐药性病原体的耐药性生物体所引起的感染。更具体地说，本发明涉及β‑内酰胺酶抑制剂化合物1或其药学上可接受的盐与舒巴坦或其药学上可接受的盐及任选的亚胺培南/西司他丁或其药学上可接受的盐的组合。

USPTO Abstract

本发明涉及β‑内酰胺酶抑制剂与舒巴坦及任选的亚胺培南/西司他丁的组合。所述组合适用于治疗细菌感染，包括由包括多重耐药性病原体的耐药性生物体所引起的感染。更具体地说，本发明涉及β‑内酰胺酶抑制剂化合物1或其药学上可接受的盐与舒巴坦或其药学上可接受的盐及任选的亚胺培南/西司他丁或其药学上可接受的盐的组合。

Drugs covered by this patent

durlobactam-sodium (DURLOBACTAM SODIUM)

Patent Metadata

Patent number: CN107108624B
Jurisdiction: CN
Classification: —
Expires: 2020-01-07
Drug substance claim: No
Drug product claim: No
Assignee: Ntassis Treatment
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.